NAGIOS: RODERIC FUNCIONANDO

Antioxidant therapies and oxidative stress in Friedreich's ataxia: the right path or just a diversion?

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Antioxidant therapies and oxidative stress in Friedreich's ataxia: the right path or just a diversion?

dc.contributor.author	Rodríguez, Laura R.
dc.contributor.author	Lapeña, Tamara
dc.contributor.author	Calap Quintana, Pablo
dc.contributor.author	Moltó Ruiz, María Dolores
dc.contributor.author	González Cabo, María Pilar
dc.contributor.author	Navarro Langa, Juan Antonio
dc.date.accessioned	2021-04-23T13:26:14Z
dc.date.available	2021-04-23T13:26:14Z
dc.date.issued	2020
dc.identifier.citation	Rodríguez, Laura R. Lapeña, Tamara Calap Quintana, Pablo Moltó Ruiz, María Dolores González Cabo, María Pilar Navarro Langa, Juan Antonio 2020 Antioxidant therapies and oxidative stress in Friedreich's ataxia: the right path or just a diversion? Antioxidants 9 8 664
dc.identifier.uri	https://hdl.handle.net/10550/78902
dc.description.abstract	Friedreich's ataxia is the commonest autosomal recessive ataxia among population of European descent. Despite the huge advances performed in the last decades, a cure still remains elusive. One of the most studied hallmarks of the disease is the increased production of oxidative stress markers in patients and models. This feature has been the motivation to develop treatments that aim to counteract such boost of free radicals and to enhance the production of antioxidant defenses. In this work, we present and critically review those 'antioxidant' drugs that went beyond the disease's models and were approved for its application in clinical trials. The evaluation of these trials highlights some crucial aspects of the FRDA research. On the one hand, the analysis contributes to elucidate whether oxidative stress plays a central role or whether it is only an epiphenomenon. On the other hand, it comments on some limitations in the current trials that complicate the analysis and interpretation of their outcome. We also include some suggestions that will be interesting to implement in future studies and clinical trials.
dc.language.iso	eng
dc.relation.ispartof	Antioxidants, 2020, vol. 9, num. 8, p. 664
dc.subject	Estrès oxidatiu
dc.subject	Antioxidants
dc.title	Antioxidant therapies and oxidative stress in Friedreich's ataxia: the right path or just a diversion?
dc.type	journal article	es_ES
dc.date.updated	2021-04-23T13:26:15Z
dc.identifier.doi	10.3390/antiox9080664
dc.identifier.idgrec	145687
dc.rights.accessRights	open access	es_ES